§ 13F · FUND PROFILE
Aisling Capital Management LP.
Institutional filer · behavioral pattern: Other. Summary pending.
AUM · $456M (13F)Positions · 14Turnover · — · Q1Filed · May 5, 2026
CONCENTRATION
—
Top 10 holdings
NEW BUYS
0
+$2M deployed
EXITS
0
No exits
SECTOR SHIFT
—
No prior quarter data
3YR HIT RATE
—
Top-5 overlap
§ 01 · TOP HOLDINGS
The book · Q1 2026
FILED MAY 5, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q1 |
|---|---|---|---|---|---|---|
| 1 | BBIO | BridgeBio Pharma Inc. (BBIO) | 5.09M | $378M | 79.4% | ±0% |
| 2 | SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | 1.32M | $31M | 6.5% | ±0% |
| 3 | GLUE | Monte Rosa Therapeutics Inc (GLUE) | 1.56M | $26M | 5.4% | +6% |
| 4 | BCAX | Bicara Therapeutics Inc. (BCAX) | 569K | $11M | 2.4% | ±0% |
| 5 | BBOT | BridgeBio Oncology Therapeutics (BBOT) | 1.02M | $9M | 1.9% | +80% |
| 6 | CMPS | Compass Pathways Plc (CMPS) | 1.43M | $8M | 1.7% | +20% |
| 7 | SRRK | Scholar Rock Holding Corporation (SRRK) | 77K | $4M | 0.8% | ±0% |
| 8 | BMEA | Biomea Fusion Inc (BMEA) | 2.05M | $3M | 0.7% | ±0% |
| 9 | EPRX | Eupraxia Pharmaceuticals Inc. (EPRX) | 325K | $2M | 0.5% | NEW |
| 10 | URGN | Urogen Pharma Ltd. (URGN) | 108K | $2M | 0.4% | ±0% |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE AISLING SIGNAL
AC read
Aisling Capital Management LP is a Other fund managing $456 million in assets. The fund runs a focused portfolio of just 14 positions.
Read the full dossier →§ 04 · FILING HISTORY
Q-by-Q deltas
2 FILINGS
Q1 2026
Steady book
+0 buys · −0 exits · 0 changed
Q4 2025
Steady book
+0 buys · −0 exits · 0 changed
Q3 2025
Steady book
+0 buys · −0 exits · 0 changed
Q2 2025
Steady book
+0 buys · −0 exits · 0 changed